Residency · Residency · Hematology Thrombosis

Acquired Coagulopathies and DIC

Introduction

Acquired coagulopathies are far more common than inherited bleeding disorders in clinical practice and represent some of the most challenging hemostatic derangements encountered in hospitalized patients. The spectrum of acquired coagulopathies ranges from liver disease and vitamin K deficiency, which alter the production of coagulation factors, to disseminated intravascular coagulation (DIC), which consumes hemostatic components through pathologic activation, and acquired factor inhibitors, which neutralize specific coagulation proteins through autoantibody formation. A mechanistic understanding of each entity is essential because the treatment approach differs fundamentally depending on the underlying pathophysiology. Empiric, indiscriminate replacement of blood products without attention to the specific coagulopathic mechanism is both ineffective and potentially harmful.

Disseminated Intravascular Coagulation (DIC)

Pathophysiology

Disseminated intravascular coagulation is always secondary to an underlying trigger and is never a primary diagnosis. This principle is foundational to both the diagnostic approach and the treatment strategy: identifying and treating the inciting cause is the single most important therapeutic intervention. The pathophysiology of DIC involves the systemic, unregulated activation of the coagulation cascade, leading to widespread generation of thrombin and deposition of fibrin within the microvasculature. This diffuse microvascular thrombosis simultaneously consumes clotting factors and platelets, creating the paradox of a disorder that is at once thrombotic and hemorrhagic.

Several interconnected mechanisms drive this pathologic process. First, tissue factor is released or expressed in response to infection, tissue injury, malignancy, or obstetric complications, resulting in massive activation of the extrinsic coagulation pathway and uncontrolled thrombin generation that overwhelms normal regulatory mechanisms. Second, the natural anticoagulant pathways become impaired: antithrombin is consumed through complex formation with the excess thrombin and activated serine proteases, and the protein C anticoagulant pathway is suppressed by inflammatory cytokines that downregulate thrombomodulin expression on endothelial surfaces. Third, fibrinolysis is dysregulated, though the direction of this dysregulation varies with the underlying cause. In sepsis-associated DIC, plasminogen activator inhibitor-1 (PAI-1) is markedly elevated, suppressing fibrinolytic capacity and favoring microvascular fibrin accumulation. In contrast, DIC associated with acute promyelocytic leukemia (APL) or major trauma is characterized by excessive fibrinolysis, which exacerbates the hemorrhagic component. Fourth, direct endothelial damage from sepsis, burns, or other insults contributes to both procoagulant activation and loss of the normal anticoagulant properties of the endothelium.

Etiology

Infection and sepsis represent the most common cause of DIC, accounting for approximately 35% of cases. Both gram-negative and gram-positive organisms can trigger DIC, with meningococcemia being the classic association due to its propensity to cause purpura fulminans. Malignancy is the second major category, with mucin-secreting adenocarcinomas of the pancreas, prostate, and lung being particularly associated with chronic or subacute DIC, while acute leukemia, especially APL with its distinctive hyperfibrinolytic DIC, represents an acute and life-threatening presentation. Obstetric emergencies including placental abruption, amniotic fluid embolism, HELLP syndrome, eclampsia, retained products of conception, and septic abortion are important causes, with the release of procoagulant material from the placenta and uterine contents being the primary mechanism. Major trauma and burns cause DIC through massive tissue destruction and release of tissue factor, phospholipids, and fat emboli. Vascular anomalies, including large aortic aneurysms and giant hemangiomas (the Kasabach-Merritt phenomenon), can produce localized intravascular coagulation that progresses to systemic DIC. Additional triggers include acute hemolytic transfusion reactions, snake envenomation, pancreatitis, acute liver failure, and heat stroke.

Clinical Manifestations

Acute DIC presents predominantly with hemorrhagic manifestations, as the consumption of clotting factors and platelets outpaces compensatory production. Patients may exhibit oozing from venipuncture sites, central line insertion points, and surgical wounds, as well as ecchymoses, petechiae, and frank hemorrhage from the gastrointestinal or pulmonary tracts. Simultaneously, microvascular thrombosis produces organ dysfunction that may include acute renal failure from glomerular and arteriolar fibrin deposition, acute respiratory distress syndrome from pulmonary microvascular thrombosis, hepatic dysfunction, and acral ischemia with peripheral gangrene.

Chronic or compensated DIC, as seen in patients with underlying malignancy, has a predominantly thrombotic presentation because the liver and bone marrow can partially compensate for the ongoing consumption by increasing production of coagulation factors and platelets. The classic clinical manifestation of chronic cancer-associated DIC is Trousseau syndrome, characterized by migratory superficial thrombophlebitis or unexplained venous thromboembolism. Laboratory values may be nearly normal or only mildly abnormal in compensated DIC, making the diagnosis more challenging.

Purpura fulminans represents the most severe form of acute DIC, manifesting as rapidly progressive symmetric peripheral gangrene with hemorrhagic skin necrosis. It is classically associated with meningococcemia and with neonatal homozygous protein C deficiency. The pathology reflects overwhelming microvascular thrombosis in the dermal and subcutaneous vessels with secondary hemorrhagic infarction.

Diagnosis (ISTH DIC Score)

The International Society on Thrombosis and Haemostasis (ISTH) developed a scoring system for the objective diagnosis of overt DIC based on routinely available laboratory parameters. The score incorporates four variables: platelet count (100,000 or above scores 0 points, 50,000 to 100,000 scores 1 point, and below 50,000 scores 2 points); D-dimer or fibrin degradation products (normal scores 0, moderate increase scores 2, and strong increase scores 3 points); prolongation of the prothrombin time (less than 3 seconds above control scores 0, 3 to 6 seconds scores 1 point, and greater than 6 seconds scores 2 points); and fibrinogen level (100 mg/dL or above scores 0, and below 100 mg/dL scores 1 point). | ISTH DIC Score Parameter | 0 Points | 1 Point | 2 Points | 3 Points |

Score ≥5 = overt DIC. Recalculate daily.

A total score of 5 or greater is compatible with overt DIC and should prompt daily recalculation to monitor progression. A score below 5 does not exclude DIC but suggests that it is not yet overt, and serial monitoring should continue.

Additional laboratory findings that support the diagnosis include schistocytes on the peripheral blood smear reflecting microangiopathic hemolytic changes from mechanical red cell fragmentation across fibrin strands, decreased antithrombin levels, and elevated thrombin-antithrombin (TAT) complexes, which provide a direct measure of in vivo thrombin generation. It is important to emphasize that fibrinogen below 100 mg/dL is the most specific laboratory finding for overt DIC, as fibrinogen is an acute-phase reactant that may be elevated at baseline in many of the clinical conditions that trigger DIC, and a "normal" fibrinogen may actually represent a significant decline from a previously elevated level.

Treatment Principles

The management of DIC rests on four principles applied in order of priority. First and most important is treatment of the underlying cause, as DIC will resolve only when the inciting trigger is removed. In sepsis, this means source control and appropriate antimicrobial therapy; in APL, initiation of all-trans retinoic acid; in obstetric emergencies, delivery of the fetus and placenta.

Second, supportive replacement therapy with blood products is indicated for patients who are actively bleeding or who are at high risk for bleeding due to planned invasive procedures. Platelets should be transfused to maintain a count above 20,000 in the setting of active bleeding or above 50,000 when invasive procedures are planned. Cryoprecipitate should be administered when the fibrinogen level falls below 100 to 150 mg/dL, with a target of above 150 mg/dL. Fresh frozen plasma at a dose of 15 to 20 mL/kg is appropriate for correction of prolonged PT and aPTT in the setting of active hemorrhage. The longstanding theoretical concern that replacement of coagulation factors "fuels the fire" of DIC by providing additional substrate for thrombin generation is not supported by clinical evidence, and blood products should not be withheld from actively bleeding patients on this basis.

Third, anticoagulation has a role in predominantly thrombotic forms of DIC, such as chronic malignancy-associated DIC or DIC presenting with clinically significant thrombotic complications. Low-dose unfractionated heparin or low-molecular-weight heparin may be considered in these settings, but anticoagulation is contraindicated in severe hemorrhagic DIC.

Fourth, antithrombin concentrate replacement has a physiologic rationale given that antithrombin is consumed in DIC, but randomized controlled trials, including the large KyberSept trial, failed to demonstrate an overall survival benefit in sepsis-associated DIC, and antithrombin replacement is not considered standard therapy.

<image>A pathophysiology and management diagram for DIC. At the top, show the four main triggers (sepsis, malignancy, obstetric, trauma) converging on the central pathogenic mechanism: tissue factor release → massive thrombin generation → simultaneous microvascular fibrin deposition (causing organ ischemia) and consumption of clotting factors/platelets (causing hemorrhage). Show the feedback loops: AT consumption, protein C pathway suppression, and PAI-1 elevation (suppressed fibrinolysis in sepsis) vs. excessive fibrinolysis (in APL/trauma). Below, display the ISTH DIC score as a scoring table with the four parameters and their point values. At the bottom, show the treatment algorithm: (1) Treat underlying cause (most important), (2) If bleeding: platelets if <20K, cryo if fibrinogen <100-150, FFP for coagulopathy, (3) If thrombotic predominant: consider heparin. Use arrows to show the dual pathology of thrombosis and hemorrhage occurring simultaneously. Medical education poster format.</image>

Liver Disease Coagulopathy

Rebalanced Hemostasis Concept

The coagulopathy of liver disease is among the most misunderstood hemostatic derangements in clinical medicine. The traditional interpretation of an elevated INR in cirrhosis as indicative of a bleeding tendency is fundamentally flawed because liver disease impairs the production of both procoagulant and anticoagulant factors, creating a new, "rebalanced" hemostatic equilibrium that cannot be accurately captured by conventional coagulation tests.

On the procoagulant side, hepatic synthetic failure leads to decreased production of factors II, V, VII, IX, X, and XI, with fibrinogen production declining only in advanced disease. On the anticoagulant side, the liver-dependent natural anticoagulants protein C, protein S, and antithrombin are equally diminished. Additionally, two important procoagulant changes occur: VWF and factor VIII are markedly elevated in liver disease because they are not cleared efficiently by the damaged liver and because endothelial activation stimulates VWF release. The net result is a hemostatic system that is precariously balanced, stable under baseline conditions but easily tipped toward either bleeding or thrombosis by any additional perturbation. The PT and INR, which reflect only the procoagulant pathway, do not reliably predict bleeding risk in liver disease. An elevated INR in cirrhosis emphatically does not mean that the patient is "anticoagulated."

Specific Abnormalities

Thrombocytopenia in liver disease is multifactorial, resulting from splenic sequestration due to portal hypertension (which can trap up to 90% of the circulating platelet mass in an enlarged spleen), decreased hepatic production of thrombopoietin, and direct alcohol-mediated bone marrow suppression. Qualitative platelet dysfunction further compounds the quantitative deficit, driven by uremia-associated platelet dysfunction in patients with hepatorenal syndrome and direct alcohol-related impairment of platelet function. Dysfibrinogenemia is a characteristic abnormality of liver disease in which the fibrinogen molecule is structurally altered by increased sialic acid content, impairing fibrin polymerization. This manifests as a disproportionately prolonged thrombin time relative to the fibrinogen level. Hyperfibrinolysis occurs due to decreased hepatic clearance of tissue plasminogen activator (tPA), resulting in elevated D-dimer levels. Vitamin K deficiency is common in cholestatic liver disease due to impaired bile salt secretion and malabsorption of fat-soluble vitamins, and may coexist with the synthetic failure of hepatocellular disease.

Management Principles

The most important principle in managing the coagulopathy of liver disease is restraint. Prophylactic correction of the INR before procedures is generally not indicated and is discouraged by contemporary guidelines, as the INR does not predict procedural bleeding risk in this population and FFP administration contributes to volume overload that exacerbates portal hypertension. Viscoelastic testing with thromboelastography (TEG) or rotational thromboelastometry (ROTEM) provides a more comprehensive and clinically useful assessment of hemostatic capacity than conventional PT/aPTT and is increasingly recommended for guiding transfusion decisions in liver disease.

When bleeding does occur, targeted replacement is appropriate: cryoprecipitate to maintain fibrinogen above 120 to 150 mg/dL, platelet transfusion to achieve a count above 50,000 for procedures, and FFP only when there is active hemorrhage with documented coagulopathy, administered judiciously to avoid the volume overload that accompanies the 250 mL per unit volume. Excessive FFP transfusion is a common iatrogenic error in liver disease management and should be actively avoided. Prothrombin complex concentrate (PCC) can be considered for urgent bleeding as it delivers concentrated coagulation factors in a small volume, though caution is warranted regarding the thrombotic risk in patients whose rebalanced hemostasis may be tipped toward thrombosis.

A critical and often underappreciated point is that venous thromboembolism occurs in patients with cirrhosis, and anticoagulation is appropriate when indicated for portal vein thrombosis, deep vein thrombosis, or pulmonary embolism. The elevated INR should not be misinterpreted as a contraindication to anticoagulation.

Vitamin K Deficiency

Causes

Vitamin K is a fat-soluble vitamin that exists in two naturally occurring forms: K1 (phylloquinone), derived from green leafy vegetables, and K2 (menaquinone), synthesized by intestinal bacteria. Dietary deficiency of vitamin K is rare in well-nourished adults but becomes clinically significant in several settings. Malabsorption is the most common mechanism, occurring in cholestatic liver disease (where bile salt deficiency impairs fat-soluble vitamin absorption), celiac disease, short bowel syndrome, and cystic fibrosis. Broad-spectrum antibiotics can precipitate vitamin K deficiency by eliminating the gut flora responsible for K2 synthesis, particularly when combined with poor dietary intake. Warfarin therapy produces pharmacologic vitamin K antagonism by inhibiting the vitamin K epoxide reductase (VKORC1) enzyme that recycles vitamin K. Hemorrhagic disease of the newborn, also termed vitamin K deficiency bleeding (VKDB), is classified into three forms: early-onset (within the first 24 hours, typically associated with maternal medications that cross the placenta), classic (days 2 through 7, the form prevented by routine neonatal vitamin K prophylaxis), and late-onset (2 to 12 weeks, occurring predominantly in exclusively breastfed infants who did not receive prophylaxis).

Vitamin K-Dependent Factors

The vitamin K-dependent coagulation factors include the procoagulant factors II, VII, IX, and X, often remembered by the mnemonic "1972" (factors 10, 9, 7, and 2), as well as the anticoagulant proteins C and S. Vitamin K serves as an essential cofactor for the gamma-carboxylase enzyme that adds gamma-carboxyl groups to glutamic acid residues on these proteins, a post-translational modification that is required for calcium-dependent binding to phospholipid surfaces and thus for biological activity. In the absence of adequate vitamin K, under-carboxylated, nonfunctional forms of these proteins (known as PIVKA, proteins induced by vitamin K absence) are produced.

Factor VII has the shortest half-life among the vitamin K-dependent factors, at approximately 6 hours. Consequently, the prothrombin time (PT), which is most sensitive to factor VII activity, is the first coagulation test to become prolonged in vitamin K deficiency. With progressive depletion, factors IX, X, and II are successively affected, and the aPTT becomes prolonged as well. This temporal sequence also explains why the PT/INR rises before the aPTT during warfarin initiation.

Treatment

Vitamin K1 (phytonadione) is the treatment of choice, with the oral route preferred when feasible. Oral vitamin K at a dose of 10 mg produces correction of the INR beginning within 12 to 24 hours. Intravenous vitamin K has a faster onset (6 to 12 hours) and is indicated when oral administration is not possible or when there is severe, life-threatening bleeding requiring rapid correction. Intravenous vitamin K must be administered as a slow infusion due to the risk of anaphylactoid reactions, which are related to the solubilizing agent in the formulation. Subcutaneous administration results in erratic and unreliable absorption and should be avoided. For warfarin reversal in the setting of major bleeding, 4-factor prothrombin complex concentrate (Kcentra) at a dose of 25 to 50 IU/kg provides immediate correction of the INR and should always be administered alongside vitamin K 10 mg intravenously, as the PCC provides only temporary factor replacement while vitamin K restores endogenous factor production.

Acquired Factor Inhibitors

Acquired Hemophilia A (Acquired Factor VIII Inhibitor)

Acquired hemophilia A is a rare but potentially devastating autoimmune disorder caused by the development of IgG autoantibodies directed against factor VIII, with an incidence of approximately 1 to 4 cases per million per year. The median age at diagnosis is 70 to 80 years, though a well-recognized bimodal distribution exists, with a smaller peak in young postpartum women. Associated conditions include autoimmune diseases, underlying malignancy, and certain medications (notably penicillin and sulfonamides), though approximately 50% of cases are idiopathic with no identifiable trigger.

The clinical presentation of acquired hemophilia A differs strikingly from congenital hemophilia in its pattern of bleeding. Patients with acquired hemophilia A typically present with severe soft tissue hemorrhage, extensive ecchymoses, mucocutaneous bleeding, and post-procedural hemorrhage. Hemarthrosis, the hallmark of congenital hemophilia, is characteristically rare in the acquired form. The diagnosis is established by identifying an isolated prolonged aPTT that fails to correct on a mixing study (demonstrating the presence of an inhibitor rather than a factor deficiency), a reduced factor VIII level, and a positive Bethesda assay quantifying the inhibitor titer. An important distinction from congenital hemophilia inhibitors is that acquired factor VIII inhibitors display non-linear (type 2) kinetics, meaning that the factor VIII level does not correlate with the inhibitor titer as predictably as in congenital hemophilia, and even low-titer inhibitors can be associated with severe bleeding.

Treatment

Management of acquired hemophilia A encompasses two parallel strategies: acute hemostatic control and inhibitor eradication. For acute bleeding, bypassing agents are the mainstay of hemostatic therapy because the inhibitor renders factor VIII replacement unreliable. Recombinant activated factor VII (rFVIIa, NovoSeven) at 90 mcg/kg every 2 to 3 hours is a first-line option that works by generating thrombin directly on activated platelet surfaces, bypassing the need for factor VIII. Activated prothrombin complex concentrate (aPCC, FEIBA) at 50 to 100 IU/kg every 8 to 12 hours is an alternative bypassing agent. Recombinant porcine factor VIII (rpFVIII, Obizur) at an initial dose of 200 IU/kg offers another option, provided the patient does not have cross-reacting anti-porcine factor VIII antibodies, which should be checked before administration.

Inhibitor eradication through immunosuppression is essential and should be initiated as soon as the diagnosis is confirmed. First-line therapy consists of prednisone at 1 mg/kg/day, either alone or in combination with cyclophosphamide at 1 to 2 mg/kg/day. Rituximab at 375 mg/m2 weekly for 4 doses is employed for patients who are refractory to or have contraindications to cyclophosphamide-based regimens. The EACH trial (GTH-AH 01/2010) demonstrated that rituximab-based regimens were non-inferior to steroids plus cyclophosphamide. Approximately 70 to 80% of patients achieve complete remission with immunosuppressive therapy, though relapse occurs in roughly 20% and necessitates retreatment.

Acquired Factor V Inhibitor

Acquired factor V inhibitors are rare autoantibodies that have been classically associated with exposure to bovine thrombin-containing topical hemostatic products during surgery, as well as with antibiotic use. The laboratory hallmark is prolongation of both the PT and aPTT (reflecting factor V's role in both the intrinsic and common pathways), a low factor V activity level, and failure to correct on mixing study. The condition is usually self-limited, and the inhibitor often resolves spontaneously over weeks to months. An important therapeutic consideration is that platelet transfusion may provide hemostatic benefit because platelet alpha granules contain factor V that is released upon activation and is partially protected from the circulating inhibitor.

Lupus Anticoagulant (LA)

The lupus anticoagulant is an IgG or IgM antibody directed against phospholipid-binding proteins, principally beta-2-glycoprotein I and prothrombin, and represents the laboratory hallmark of antiphospholipid syndrome. Despite its name, the lupus anticoagulant is a misnomer on two counts: it is not specific to systemic lupus erythematosus, and it is not an anticoagulant in vivo. Rather, it prolongs phospholipid-dependent clotting tests in vitro by interfering with the phospholipid reagent, while in vivo it is strongly associated with thrombosis through mechanisms that include endothelial cell activation, complement activation, and interference with natural anticoagulant pathways.

The diagnostic approach to lupus anticoagulant follows a three-step algorithm: first, demonstration of prolongation of a phospholipid-dependent clotting test (dilute Russell viper venom time or a lupus-sensitive aPTT); second, confirmation that this prolongation does not correct upon mixing with normal plasma, ruling out factor deficiency; and third, demonstration that the prolongation corrects with the addition of excess phospholipid (platelet neutralization procedure or hexagonal-phase phospholipid assay), confirming phospholipid dependence. Distinguishing a lupus anticoagulant from a specific factor inhibitor is clinically critical because they represent diametrically opposite clinical entities: the lupus anticoagulant is associated with thrombosis, while a factor inhibitor is associated with hemorrhage.

Key Clinical Pearls

• DIC is always secondary; the cornerstone of treatment is addressing the underlying cause; factor replacement is supportive and indicated for active bleeding
• Fibrinogen <100 mg/dL is the most specific lab finding for overt DIC; always check fibrinogen and do not rely on PT/aPTT alone
• In liver disease, the INR does NOT predict bleeding risk; "rebalanced hemostasis" means patients are at risk for both bleeding AND thrombosis; TEG/ROTEM are more informative
• Acquired hemophilia A should be suspected in any elderly patient with new-onset severe bleeding and an isolated prolonged aPTT that fails to correct on mixing study
• Factor VII has the shortest half-life of vitamin K-dependent factors (~6 hours); PT/INR is the first test to become prolonged in vitamin K deficiency or warfarin initiation
• A prolonged aPTT that does not correct on mixing can be either a lupus anticoagulant (thrombotic) or a factor inhibitor (hemorrhagic); the clinical context is critical for distinguishing these opposite conditions

References

1. Levi M, Scully M. How I treat disseminated intravascular coagulation. Blood. 2018;131(8):845-854.
2. Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med. 2011;365(2):147-156.
3. Tiede A, et al. International recommendations on the diagnosis and treatment of acquired hemophilia A. Haematologica. 2020;105(7):1791-1801.
4. Taylor FB Jr, et al. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation (ISTH DIC score). Thromb Haemost. 2001;86(5):1327-1330.
5. Knoebl P, et al. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). J Thromb Haemost. 2012;10(4):622-631.

Read this lecture as Markdown